Quentis Therapeutics Inc.'s $48 million in series A money will help, among other things, put into the clinic next year a small-molecule IRE1 alpha inhibitor for proof-of-concept work. Going after cancer immunotherapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment (TME), Quentis will use the funds to push the leading prospect through clinical proof of concept, develop a pipeline of preclinical programs, and beef up the company's team.